Onco-Innovations Limited (NEO:ONCO)
Canada · Delayed Price · Currency is CAD | Market Cap | 38.72M -62.5% |
| Revenue (ttm) | 154.67K |
| Net Income | -14.92M |
| EPS | -0.32 |
| Shares Out | 59.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 210,550 |
| Open | 0.6500 |
| Previous Close | 0.6300 |
| Day's Range | 0.6200 - 0.8500 |
| 52-Week Range | 0.5000 - 2.2200 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Onco-Innovations
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3′-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. The company has a strategic collaboration with Nucro-Technics Inc. for the development of bioanalytical methods to support preclinical pharmacokinetic and biodistribution studies. Onco-Innovations Limited is headquartered in C... [Read more]
Financial Performance
Financial StatementsNews
Onco-Innovations Initiates ADME Studies Supporting Development of ONC010
Vancouver, Canada – July 16, 2026 – TheNewswire - Onco-Innovations Limited ( CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H , WKN: A3EKSZ) (" Onco " or the " Company ”) announces, further to its new...
Onco-Innovations Announces Entry into Loan Agreements
Vancouver, Canada – July 15, 2026 - TheNewswire – Onco-Innovations Limited (CBOE: ONCO) (“ Onco ” or the “ Company ”) announces that it has entered into three loan agreements with certain lenders pro...
Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API
VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its ...
Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE:ONCO) ("Onco" or the "Com...
Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010
VANCOUVER, BC / ACCESS Newswire / June 30, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news...
Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
VANCOUVER, BC / ACCESS Newswire / June 26, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the initiation of hepatocyte and...
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Development of PNKP Inhibitors in Oncology Drug Development
AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featur...
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Leading Out in Developing Fresh Wave of Inhibitor Classes
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) today announces its placement in an editorial published by BioMedWire (BMW), one of...
Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
VANCOUVER, BC / ACCESS Newswire / June 23, 2026 / Onco-Innovations Limited (NEO:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a...
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Also Announces Appointment of Mr. Dave Antony as CFO VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN:A3EKSZ) ("Onco" or the "...
Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
VANCOUVER, BC / ACCESS Newswire / June 16, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news...
Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology
VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the initiation of pro...
Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program
VANCOUVER, BC / ACCESS Newswire / June 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered i...
Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
Also Announces Marketing Program VANCOUVER, BC / ACCESS Newswire / June 2, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company") announces,...
Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program
VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news ...
Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
VANCOUVER, BC / ACCESS Newswire / May 15, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has advanced ...
Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Aim is to Predict Oncology Outcomes using Multimodal Artificial Intelligence VANCOUVER, BC / ACCESS Newswire / May 12, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A...
Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
VANCOUVER, BC / ACCESS Newswire / May 8, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that Nucro-Technics Inc. ("Nucro-Tec...
Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation
VANCOUVER, BC / ACCESS Newswire / May 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Inka Health Corp. ...
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Also Announces Extension of IR Program VANCOUVER, BC / ACCESS Newswire / May 1, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pl...
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announced, further to its news release date...
Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has advance...
Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program
VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of a s...
Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
VANCOUVER, BC / ACCESS Newswire / April 17, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointments o...
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
Company also announces Marketing Engagement VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / Onco-Innovations Limited (CBOECA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company")...